Eton Pharmaceuticals (ETON)
(Real Time Quote from BATS)
$3.58 USD
+0.13 (3.77%)
Updated Apr 29, 2024 02:40 PM ET
3-Hold of 5 3
B Value A Growth F Momentum B VGM
Balance Sheet
Fiscal Year End for Eton Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 21 | 16 | 14 | 21 | 12 |
Receivables | 3 | 2 | 5 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 1 | 1 | 1 | 0 |
Other Current Assets | 1 | 1 | 3 | 2 | 2 |
Total Current Assets | 27 | 20 | 24 | 25 | 15 |
Net Property & Equipment | 0 | 0 | 0 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 5 | 5 | 4 | 1 | 1 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 32 | 25 | 27 | 26 | 17 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 2 | 2 | 1 |
Current Portion Long-Term Debt | 5 | 1 | 1 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 9 | 4 | 1 | 1 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 16 | 6 | 5 | 4 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 5 | 5 | 7 | 5 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 16 | 12 | 10 | 11 | 7 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 120 | 116 | 112 | 108 | 75 |
Retained Earnings | -104 | -103 | -94 | -92 | -64 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 15 | 13 | 18 | 16 | 11 |
Total Liabilities & Shareholder's Equity | 32 | 25 | 27 | 26 | 17 |
Total Common Equity | 15 | 13 | 18 | 16 | 11 |
Shares Outstanding | 25.60 | 25.30 | 24.60 | 24.20 | 17.80 |
Book Value Per Share | 0.60 | 0.52 | 0.72 | 0.65 | 0.59 |
Fiscal Year End for Eton Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 21 | 22 | 22 | 15 |
Receivables | NA | 3 | 4 | 3 | 3 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 1 | 1 | 1 | 0 |
Other Current Assets | NA | 1 | 1 | 1 | 1 |
Total Current Assets | NA | 27 | 27 | 26 | 19 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 5 | 4 | 4 | 5 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 32 | 32 | 31 | 24 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 2 | 2 | 1 |
Current Portion Long-Term Debt | NA | 5 | 2 | 2 | 1 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 9 | 7 | 6 | 5 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 16 | 10 | 10 | 7 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 4 | 5 | 5 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 16 | 15 | 14 | 13 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 120 | 119 | 118 | 117 |
Retained Earnings | NA | -104 | -102 | -101 | -106 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 15 | 17 | 17 | 11 |
Total Liabilities & Shareholder's Equity | NA | 32 | 32 | 31 | 24 |
Total Common Equity | 0 | 15 | 17 | 17 | 11 |
Shares Outstanding | 25.60 | 25.60 | 25.60 | 25.50 | 25.50 |
Book Value Per Share | 0.00 | 0.60 | 0.66 | 0.66 | 0.44 |